Drug · CHEMBL809
SERTRALINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. SERTRALINE. Drugs and targets, record CHEMBL809. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL809
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | Serotonin transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6532 |
Source ChEMBL
Diseases56
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 56Source Open Targets
See all 56 diseasesTrials283
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01360866 | Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | Phase 3 | 2,944 | 2018-09-17 | sertraline | Its name | ClinicalTrials.gov |
| NCT02497287 | A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression | Phase 3 | 802 | 2019-04-29 | sertraline | Its name | ClinicalTrials.gov |
| NCT00666757 | A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression | Phase 4 | 750 | 2010-06-15 | sertraline | Its name | ClinicalTrials.gov |
| NCT02493868 | A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression | Phase 3 | 719 | 2019-05-21 | sertraline | Its name | ClinicalTrials.gov |
| NCT04597190 | Sequenced Treatment Effectiveness for Posttraumatic Stress | Phase 4 | 700 | 2025-03-26 | sertraline | Its name | ClinicalTrials.gov |
| NCT02655354 | A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity | 635 | 2021-07-02 | sertraline | Its name | ClinicalTrials.gov | |
| NCT04174170 | Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder | Phase 3 | 591 | 2025-05-30 | sertraline | Its name | ClinicalTrials.gov |
| NCT00052078 | Child and Adolescent Anxiety Disorders (CAMS) | Phase 3 | 488 | 2017-04-25 | sertraline | Its name | ClinicalTrials.gov |
| NCT00078286 | Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure | Phase 2/3 | 469 | 2013-02-27 | sertraline | Its name | ClinicalTrials.gov |
| NCT01802385 | Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis | Phase 3 | 460 | 2020-01-13 | sertraline | Its name | ClinicalTrials.gov |
1 to 10 of 283
See all 283 trialsComparisons in its trials102
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intervention vs Usual Care: deaths from any cause | 6 of 265 | 3 of 370 | 635 | NCT02655354 | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | 15 of 265 | 13 of 370 | 635 | NCT02655354 | Trial comparisons |
| Sertraline vs Placebo: serious adverse events | 57 of 234 | 63 of 235 | 469 | NCT00078286 | Trial comparisons |
| Sertraline 400mg vs Placebo: Number of Participants Experiencing IRIS OR Relapse | 5 of 229 | 9 of 231 | 460 | NCT01802385 | Trial comparisons |
| Sertraline 400mg vs Placebo: Count of Participants With Cerebrospinal Fluid Sterility | 101 of 229 | 90 of 231 | 460 | NCT01802385 | Trial comparisons |
| Sertraline 400mg vs Placebo: Event Free Survival | 103 of 229 | 116 of 231 | 460 | NCT01802385 | Trial comparisons |
| Sertraline 400mg vs Placebo: Survival | 109 of 229 | 125 of 231 | 460 | NCT01802385 | Trial comparisons |
| Sertraline 400mg vs Placebo: deaths from any cause | 120 of 229 | 106 of 231 | 460 | NCT01802385 | Trial comparisons |
| Sertraline 400mg vs Placebo: serious adverse events | 141 of 229 | 121 of 231 | 460 | NCT01802385 | Trial comparisons |
| Placebo + Assigned ADT vs SAGE-217 + Assigned ADT: deaths from any cause | 0 of 220 | 0 of 220 | 440 | NCT04476030 | Trial comparisons |
1 to 10 of 102
See all 102 comparisons in its trialsPapers from its trials461
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials20
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Learning | 5 | 1 | ConductCognition |
| Trail Making Test B | 4 | 1 | ConductCognition |
| Trail Making Test A | 3 | 0 | ConductCognition |
| Card Sorting Test (Berg) | 2 | 0 | ConductCognition |
| Category Fluency | 2 | 0 | ConductCognition |
| Continuous Performance Test | 2 | 0 | ConductCognition |
| Symbol Coding | 2 | 0 | ConductCognition |
| Choice Reaction Time | 1 | 1 | ConductCognition |
| Design Fluency Test | 1 | 0 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
1 to 10 of 20
See all 20 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL809
GET https://conductscience.org/api/drugs/v1/CHEMBL809/diseases?page=2